FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Hong

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Concepts & Ideas

Activities & Behaviors

Clinical Trials, Phase I as Topic

Procedures

Physiology

Mutation

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
David S Hong; Eucharia C Iwuanyanwu; Gerald S Falchook; Goldy C George; Xiudong Lei; Reena H Mistry; Sarina A Piha-Paul; Bahareh Tavana; Jennifer J Wheler; Razelle Kurzrock
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.
David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Floyd Christopher Holsinger; David S Hong; Filip Janku; Sarina Anne Piha-Paul; Apostolia-Maria Tsimberidou; Johnique T Atkins; Razelle Kurzrock
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Hong (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David S Hong; Eucharia C Iwuanyanwu; Gerald S Falchook; Goldy C George; Xiudong Lei; Reena H Mistry; Sarina A Piha-Paul; Bahareh Tavana; Jennifer J Wheler; Razelle Kurzrock
Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.
Journal of cancer research and clinical oncology 2013;139(6):963-70.
2013: David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Cancer treatment reviews 2013;39(4):375-87.
2013: Floyd Christopher Holsinger; David S Hong; Filip Janku; Sarina Anne Piha-Paul; Apostolia-Maria Tsimberidou; Johnique T Atkins; Razelle Kurzrock
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):e137-40.
2013: J J Wheler; S S Chen; G S Falchook; J Y Fok; S Fu; David S Hong; Filip Janku; Aung Naing; S A Piha-Paul; B Stephen; A M Tsimberidou; R Kurzrock
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(3):838-42.
2013: Gerald S Falchook; Siqing Fu; David S Hong; Yunfang Jiang; Sonia K Morgan-Linnell; Aung Naing; Sarina A Piha-Paul; Apostolia M Tsimberidou; Jennifer J Wheler; Ralph G Zinner; Christel Bastida; Razelle Kurzrock
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Oncotarget 2013;4(1):118-27.
2013: Ishwaria M Subbiah; Vivek Subbiah; Apostolia M Tsimberidou; Jennifer J Wheler; Robert A Wolff; Aung Naing; Sarina Piha-Paul; Gerald S Falchook; Siqing Fu; Kenneth R Hess; David S Hong; Filip Janku; Milind Javle; Ahmed O Kaseb; Razelle Kurzrock
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Oncotarget 2013;4(1):156-65.
2013: Filip Janku; Gerald S Falchook; Siqing Fu; David S Hong; J Jack Lee; Rajyalakshmi Luthra; Aung Naing; Sarina A Piha-Paul; Vanda M Stepanek; Apostolia M Tsimberidou; Jennifer J Wheler; Razelle Kurzrock
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Cancer research 2013;73(1):276-84.
2012: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; Jack J Lee; Rajyalakshmi Luthra; Stacy L Moulder; Aung Naing; Sarina A Piha-Paul; Vanda M Stepanek; Apostolia M Tsimberidou; Jennifer J Wheler; Razelle Kurzrock
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Oncotarget 2012;3(12):1566-75.
2012: David S Hong; Scott Kopetz; Gerald Falchook; Siqing Fu; Ignacio Garrido-Laguna; Aung Naing; Jesal C Patel; Apostolia M Tsimberidou; Jennifer Wheler; Sijin Win; Razelle Kurzrock
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.
Clinical colorectal cancer 2012;11(4):297-303.
2012: Apostolia-Maria Tsimberidou; Sijin Wen; Jennifer J Wheler; Yang Ye; Donald Berry; Gerald S Falchook; Siqing Fu; David S Hong; Nancy G Iskander; Filip Janku; Rajyalakshmi Luthra; Aung Naing; Sarina Piha-Paul; Razelle Kurzrock
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(22):6373-83.
2012: J J Wheler; G S Falchook; S Fu; David S Hong; S Moulder; Aung Naing; B Stephen; A M Tsimberidou; S Wen; R Kurzrock
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(8):1963-7.
2012: David S Hong; Sergej Konoplev; Marina Konopleva; Donald Kufe; Razelle Kurzrock; Donald Lawrence; Hillard Lazarus; Colin J Meyer; James Mier; Aung Naing; Geoffrey I Shapiro; Jeffrey G Supko; Jennifer Wheler; Michael Andreeff; Joseph Paul Eder; Deborah A Ferguson; Xiaoying He; Bruce J Dezube
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(12):3396-406.
2012: Apostolia M Tsimberidou; Sijin Wen; Joann Lim; Aung Naing; Ishwaria M Subbiah; Adoneca H Fortier; Siqing Fu; David S Hong; Razelle Kurzrock
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
Hepato-gastroenterology 2012;59(116):960-4.
2012: Aung Naing; Patricia M LoRusso; Joseph Ludwig; Pete Anderson; Robert S Benjamin; Helen X Chen; Laurence A Doyle; Siqing Fu; David S Hong; Razelle Kurzrock
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2625-31.
2012: G S Falchook; David S Hong; J Lim; Aung Naing; J Wheler; M Duvic; Razelle Kurzrock
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2012;69(5):1117-26.
2012: Matthew D Galsky; David S Hong; Daniel Mulkerin; William K Oh; L H Camacho; E G Chiorean; Dean F Bajorin
Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(4):1037-44.
2012: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; J Jack Lee; Karen H Lu; Rajyalakshmi Luthra; Stacy L Moulder; Aung Naing; Apostolia-Maria Tsimberidou; Shannon N Westin; Jennifer J Wheler; Razelle Kurzrock
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(8):777-82.
2012: Ignacio Garrido-Laguna; David S Hong; Filip Janku; Aung Naing; Apostolia M Tsimberidou; Christos Vaklavas; Sijin Wen; Gerald S Falchook; Siqing Fu; Razelle Kurzrock
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Cancer 2012;118(5):1422-8.
2012: Vivek Subbiah; Ian E McCutcheon; John M Slopis; Jackson Hamilton; David S Hong; Leena M Ketonen; Razelle Kurzrock
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):e64-8.
2012: Ignacio Garrido-Laguna; David S Hong; Filip Janku; Rajyalakshmi Luthra; Aung Naing; Ly M Nguyen; Xuemei Wang; Jenifer J Wheler; Gerald S Falchook; Siqing Fu; Razelle Kurzrock
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
PloS one 2012;7(5):e38033.
2011: Aung Naing; Saneese K Stephen; Jennifer J Wheler; Xiudong Lei; Chandtip Chandhasin; Gerald Falchook; Moshe Frenkel; Siqing Fu; David S Hong; Razelle Kurzrock
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
Cancer 2011;117(22):5142-50.
2011: John W Moroney; Stacy Moulder; Aung Naing; Matthew P Schlumbrecht; Diane C Bodurka; Robert L Coleman; Thorunn Helgason; David S Hong; Filip Janku; Razelle Kurzrock
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6840-6.
2011: David S Hong; Sunil K Kadam; Razelle Kurzrock; Funda Meric-Bernstam; Aung Naing; Aejaz Nasir; Yun Oh; Valérie André; Les Brail; Sophie Callies; Mayer Fishman; Timothy R Holzer; Jennifer Wheler; George Simon
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6582-91.
2011: Siqing Fu; David S Hong; Adrienne Howard; Aung Naing; Joseph Nates; Kristen Price; Sijin Wen; Jennifer Wheler; Diane Barber; Gerald Falchook; Razelle Kurzrock
Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):3547-52.
2011: Matthew D Galsky; David S Hong; Daniel Mulkerin; William K Oh; Sonia Seng; Luis H Camacho; Elena G Chiorean; Dean F Bajorin
Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Clinical genitourinary cancer 2011;9(1):27-30.
2011: Filip Janku; David S Hong; David J McConkey; Razelle Kurzrock
Autophagy as a target for anticancer therapy.
Nature reviews. Clinical oncology 2011;8(9):528-39.
2011: Razelle Kurzrock; Ranee Mehra; Thomas Müller; Forlisa Nauling; Chaan S Ng; David G Pfister; Mark J Ratain; Douglas W Ball; Ezra E W Cohen; Roger B Cohen; Arlene A Forastiere; John Frye; Robert F Gagel; David S Hong; Linda Janisch; Steven I Sherman; Lei Ye; Ravi Salgia
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(19):2660-6.
2011: Siqing Fu; David S Hong; Kirk S Culotta; Gerald S Falchook; Timothy L Madden; David C Madoff; Stacy L Moulder; Aung Naing; Chaan S Ng; Razelle Kurzrock
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.
Molecular cancer therapeutics 2011;10(7):1300-7.
2011: Sarina A Piha-Paul; David S Hong; Razelle Kurzrock
Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(12):e333-5.
2011: David S Hong; Maria Cabanillas; Jennifer Wheler; Aung Naing; Apostolia-Maria Tsimberidou; Lei Ye; Steven G Waguespack; Mike Hernandez; Adel K El Naggar; Savita Bidyasar; John Wright; Steven I Sherman; Naifa L Busaidy; Alder K El Naggar; Razelle Kurzrock
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
The Journal of clinical endocrinology and metabolism 2011;96(4):997-1005.
2011: Filip Janku; Apostolia-Maria Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S Hong; Aung Naing; Gerald S Falchook; John W Moroney; Sarina A Piha-Paul; Jennifer J Wheler; Stacy L Moulder; Siqing Fu; Razelle Kurzrock
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Molecular cancer therapeutics 2011;10(3):558-65.
2011: Filip Janku; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; David S Hong; J Jack Lee; Rajyalakshmi Luthra; Aung Naing; Apostolia-Maria Tsimberidou; Razelle Kurzrock
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
PloS one 2011;6(7):e22769.
2011: Filip Janku; Apostolia-Maria Tsimberidou; Xuemei Wang; David S Hong; Aung Naing; Jing Gong; Ignacio Garrido-Laguna; Henrique A Parsons; Ralph G Zinner; Razelle Kurzrock
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
The oncologist 2011;16(3):327-35.
2010: Luis H Camacho; Sheila Garcia; Amar M Panchal; JoAnn Lim; David S Hong; Chaan Ng; David C Madoff; Siqing Fu; Isis Gayed; Razelle Kurzrock
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Clinical colorectal cancer 2010;9(5):311-4.
2010: Apostolia-Maria Tsimberidou; Wallace Akerley; Matthias Schabel; David S Hong; Cynthia Uehara; Anil Chhabra; Terri Warren; Gary G Mather; Brent A Evans; Deane P Woodland; Edward A Swabb; Razelle Kurzrock
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
Molecular cancer therapeutics 2010;9(12):3410-9.
2010: Ignacio Garrido-Laguna; Filip Janku; Gerald S Falchook; Siqing Fu; David S Hong; Aung Naing; Joanne Aaron; Xuemei Wang; Merrill Kies; Razelle Kurzrock
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):4031-7.
2009: David S Hong; Said M Sebti; Robert A Newman; Michelle A Blaskovich; Lei Ye; Robert F Gagel; Stacy Moulder; Jennifer J Wheler; Aung Naing; Nizar M Tannir; Chaan S Ng; Steven I Sherman; Adel K El-Naggar; Rabia Khan; Jonathan Trent; John J Wright; Razelle Kurzrock
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):7061-8.
2009: Apostolia-Maria Tsimberidou; Luis H Camacho; Srdan Verstovsek; Chaan Ng; David S Hong; Cynthia K Uehara; Catalina Gutierrez; Shawn Daring; Jan Stevens; Philip B Komarnitsky; Brian Schwartz; Razelle Kurzrock
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4769-76.
2007: David S Hong; Laura S Angelo; Razelle Kurzrock
Interleukin-6 and its receptor in cancer: implications for translational therapeutics.
Cancer 2007;110(9):1911-28.
2006: David S Hong; James L Abbruzzese; Karla R Bogaard; Yvonne Lassere; Masakazu Fukushima; Akira Mita; Keizo Kuwata; Paulo M Hoff
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Cancer 2006;107(6):1383-90.
2006: Jose G Trevino; Justin M Summy; Donald P Lesslie; Nila U Parikh; David S Hong; Francis Y Lee; Nicholas J Donato; James L Abbruzzese; Cheryl H Baker; Gary E Gallick
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
The American journal of pathology 2006;168(3):962-72.
2003: David S Hong; Kalen L Jacobson; Issam I Raad; Marcos De Lima; Paolo Anderlini; Gregory N Fuller; Cindy Ippoliti; Rita M Cool; Norman E Leeds; Aida Narvios; Xiang Y Han; Anthony Padula; Richard E Champlin; Chitra Hosing
West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(8):1044-9.